一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (687k)
Article in Japanese

Case Report

Pneumothorax in lung adenocarcinoma on chemotherapy with bevaciuzumab

Reiko Yoshino  Noriaki Sunaga  Yasuki Iwasaki  Takeshi Hisada  Tamotsu Ishizuka  Masatomo Mori 

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine

ABSTRACT

A 60-year-old man who underwent treatment for diabetes mellitus showed elevated levels of serum carcinoembryonic antigen . Positron emission tomography-computed tomography (CT) revealed increased18F-fluoro-deoxyglucose uptake in a pulmonary nodular lesion in the right lower lobe and mediastinal lymph nodes. He was pathologically diagnosed as having primary lung adenocarcinoma (T2N3M0, clinical stage IIIB), and systemic chemotherapy consisting of carboplatin, paclitaxel, and bevacizumab was initiated. Eighteen days later, pneumothorax occurred in the right lung and drainage was done. After one course of chemotherapy, significant tumor shrinkage with cavity formation of the primary lesion was observed on a chest CT scan. Chemotherapy was then continued with no recurrence of pneumothorax. After four courses of chemotherapy, bevacizumab maintenance was continued for 15 months from the initiation of chemotherapy to primary tumor regrowth. Pneumothorax is a rare complication of chemotherapy for malignancy. We report a rare case of pneumothorax on chemotherapy with bevacizumab for primary lung adenocarcinoma.

KEYWORDS

Lung cancer  Chemotherapy  Pneumothorax  Bevacizumab 

Received 17 Jun 2011 / Accepted 21 Oct 2011

AJRS, 1(2): 141-145, 2012

Google Scholar